Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. 1995

N Hiramatsu, and N Hayashi, and A Kasahara, and H Hagiwara, and T Takehara, and Y Haruna, and M Naito, and H Fusamoto, and T Kamada
First Department of Medicine, Osaka University Medical School, Japan.

To investigate the histological change (change of liver fibrosis) produced by the anti-viral effect of interferon on hepatitis C virus, 40 patients with chronic hepatitis C treated with natural interferon alpha were divided according to the existence of viremia at the end of treatment and 6 months after the end of treatment. The condition of liver fibrosis was scored numerically with a new "hepatic fibrosis score" which is sensitive to more subtle changes than Knodell's fibrosis score. Each portal zone was evaluated separately. End-of-treatment biopsy for the HCV RNA-negative group (negative for HCV RNA at the end of treatment) showed a significant improvement of the "hepatic fibrosis score" as well as the alleviation of necrosis and inflammation. At the end of treatment and 6 months after that, serum procollagen type III peptide levels and serum type IV collagen-7s levels had also decreased significantly in the HCV RNA-negative group. The present study showed that treatment with interferon alpha could alleviate fibrosis in addition to necrosis and inflammation.

UI MeSH Term Description Entries
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009336 Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011347 Procollagen A biosynthetic precursor of collagen containing additional amino acid sequences at the amino-terminal and carboxyl-terminal ends of the polypeptide chains. Protocollagen,Procollagen Type M
D003094 Collagen A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH). Avicon,Avitene,Collagen Felt,Collagen Fleece,Collagenfleece,Collastat,Dermodress,Microfibril Collagen Hemostat,Pangen,Zyderm,alpha-Collagen,Collagen Hemostat, Microfibril,alpha Collagen
D005260 Female Females
D006521 Hepatitis, Chronic INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors. Chronic Hepatitis,Cryptogenic Chronic Hepatitis,Hepatitis, Chronic, Cryptogenic,Hepatitis, Chronic Active,Hepatitis, Chronic Persistent,Chronic Active Hepatitis,Chronic Hepatitis, Cryptogenic,Chronic Persistent Hepatitides,Chronic Persistent Hepatitis,Hepatitis, Cryptogenic Chronic
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis

Related Publications

N Hiramatsu, and N Hayashi, and A Kasahara, and H Hagiwara, and T Takehara, and Y Haruna, and M Naito, and H Fusamoto, and T Kamada
July 1997, Journal of clinical gastroenterology,
N Hiramatsu, and N Hayashi, and A Kasahara, and H Hagiwara, and T Takehara, and Y Haruna, and M Naito, and H Fusamoto, and T Kamada
November 1998, Alimentary pharmacology & therapeutics,
N Hiramatsu, and N Hayashi, and A Kasahara, and H Hagiwara, and T Takehara, and Y Haruna, and M Naito, and H Fusamoto, and T Kamada
May 1999, Digestive diseases and sciences,
N Hiramatsu, and N Hayashi, and A Kasahara, and H Hagiwara, and T Takehara, and Y Haruna, and M Naito, and H Fusamoto, and T Kamada
January 2003, Revista de gastroenterologia de Mexico,
N Hiramatsu, and N Hayashi, and A Kasahara, and H Hagiwara, and T Takehara, and Y Haruna, and M Naito, and H Fusamoto, and T Kamada
September 2012, Transplant international : official journal of the European Society for Organ Transplantation,
N Hiramatsu, and N Hayashi, and A Kasahara, and H Hagiwara, and T Takehara, and Y Haruna, and M Naito, and H Fusamoto, and T Kamada
May 1993, Journal of medical virology,
N Hiramatsu, and N Hayashi, and A Kasahara, and H Hagiwara, and T Takehara, and Y Haruna, and M Naito, and H Fusamoto, and T Kamada
October 1998, The American journal of gastroenterology,
N Hiramatsu, and N Hayashi, and A Kasahara, and H Hagiwara, and T Takehara, and Y Haruna, and M Naito, and H Fusamoto, and T Kamada
January 1995, Hormone research,
N Hiramatsu, and N Hayashi, and A Kasahara, and H Hagiwara, and T Takehara, and Y Haruna, and M Naito, and H Fusamoto, and T Kamada
November 2005, Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA,
N Hiramatsu, and N Hayashi, and A Kasahara, and H Hagiwara, and T Takehara, and Y Haruna, and M Naito, and H Fusamoto, and T Kamada
December 2004, Nature clinical practice. Gastroenterology & hepatology,
Copied contents to your clipboard!